Esperion (ESPR) CLO Benjamin Looker Receives Equity Award

What Happened
Benjamin Looker, Chief Legal Officer of Esperion Therapeutics (ESPR), was granted equity awards on 2026-03-13 totaling 570,070 shares. The filing shows two award entries: 300,840 shares granted outright and 269,230 shares reported as a derivative award, each with an acquisition price of $0.00 (no cash paid). These are compensation awards rather than open‑market purchases or sales.

Key Details

• Transaction date: 2026-03-13; Form 4 filed 2026-03-16.
• Awards: 300,840 shares (A) and 269,230 shares (A, derivative) — total 570,070 shares.
• Price: $0.00 per share (typical for restricted stock/RSU-type awards; no cash paid).
• Vesting: Per footnote, the award vests over four years in equal quarterly installments; first vesting date is June 15, 2026.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Form 4 filed 3/16/2026 reporting the 3/13/2026 grants (filing date shown on accession).

Context
These entries are awards (transaction code A) and one is recorded as a derivative — commonly RSUs or similar — meaning the shares are subject to vesting and are not immediately transferrable. Such compensation grants are routine for executives and reflect company pay, not an open‑market purchase or sale; they should not be interpreted as a direct buy/sell signal.